Provided by Tiger Fintech (Singapore) Pte. Ltd.

Qudian Inc.

2.97
-0.0200-0.67%
Post-market: 2.970.00000.00%16:04 EDT
Volume:135.77K
Turnover:402.38K
Market Cap:490.43M
PE:12.02
High:3.00
Open:2.98
Low:2.94
Close:2.99
Loading ...

The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics

Zacks
·
21 Mar

Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More

Zacks
·
21 Mar

EVgo And 2 Additional Promising Penny Stocks

Simply Wall St.
·
20 Mar

Qudian Inc. Reports 2024 Financial Results Amidst Competitive Challenges

TIPRANKS
·
20 Mar

Qudian: Q4 Earnings Snapshot

Associated Press Finance
·
20 Mar

Qudian Q4 EPS $0.05 Up From $(0.08) YoY, Sales $7.20M Down From $8.98M YoY

Benzinga
·
20 Mar

Qudian Inc: Qtrly Non-Gaap Net Income per Diluted Ads Was RMB0.37(US$0.05)

THOMSON REUTERS
·
20 Mar

Qudian Q4 Income From Operations RMB -111.278 Million

THOMSON REUTERS
·
20 Mar

Qudian Inc. Reports Fourth Quarter and Full Year 2024 Unaudited Financial Results

THOMSON REUTERS
·
20 Mar

INCY Stock Down on Disappointing Skin Disease Study Data

Zacks
·
19 Mar

ZJK Industrial Showcases Advanced Quick Disconnect Components at NVIDIA’s GTC25 Conference

GlobeNewswire
·
17 Mar

Geneva-based SGS Certifies Samsung Electronics' QD TV Sheet as Cadmium-Free

MT Newswires Live
·
12 Mar

Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

GlobeNewswire
·
10 Mar

Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress

PR Newswire
·
28 Feb

Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

GlobeNewswire
·
27 Feb

February 2025's Top US Penny Stocks To Watch

Simply Wall St.
·
19 Feb

Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering

Business Wire
·
18 Feb

New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer

Business Wire
·
16 Feb

QD Laser, Inc. Reports Mixed Financial Results Amid Sales Growth

TIPRANKS
·
13 Feb

QD Laser 9-Mos Parent Loss Y328.00M Vs Loss Y369.00M

Dow Jones
·
13 Feb